Clinic business

Khiron opens a new medical cannabis clinic in Colombia

  • Khiron opens his 4th Zerenia brand medical cannabis clinic in the city of Bogotá
  • The new clinic, with a capacity of up to 40,000 consultations per year, could add 20% to the existing capacity in Colombia
  • Located in Plaza Central, one of Bogota busiest shopping centers with more than 150,000 visitors per month
  • Adjacent to the referral sites of 4 of the largest insurance companies in Colombia
  • Continues Khiron’s unique patient acquisition strategy through its network of Zerenia™ clinics. In 2021, the Company sold over 51,800 units of medical cannabis in Colombiaup more than 900% compared to 2020

TORONTO, January 31, 2022 /PRNewswire/ – Khiron Life Sciences Corp. (“Khiron” or the “Company”) (TSXV: KHRN)(OTCQX: KHRNF)(Frankfurt: A2JMZC), a vertically integrated cannabis leader with core businesses in Latin America and Europeannounced today the official opening of its new medium-sized medical cannabis clinic under its Zerenia™ brand, in the city of Bogotá in Colombia. The new clinic is strategically located in the heart of the city of 8 million people in one of its busiest shopping malls, next to 4 of Colombia major insurance companies.

The new location, named Zerenia™ Americas, is 4,000 square feet. It includes 11 consultation rooms, with a maximum capacity of 40,000 annual consultations, and will expand Khiron’s patient capacity by more than 20% by Colombia.

“We are excited about this new Zerenia™ format and our ability to treat more patients and create closer relationships with insurance companies in Colombia. Our network of Zerenia™ clinics now has over 13 locations in Colombia, Peru, and in the UK, and we will soon be opening new locations around the world. Our unique strategy has allowed us to increase medical cannabis sales by more than 900% by Colombia in 2021, increasing patient conversion and retention rates. The selection of this new location follows a deep desire to be closer to our patients and provide insurance companies with better access for their patients while maintaining the service standards that make Zerenia™ a global network. of leading medical cannabis clinics. “, commented Alvaro Torres, CEO and Director of Khiron. “Now that the Colombian government has mandated medical cannabis coverage by all insurance companies, we believe this new localization strategy will continue to drive significant growth and profitability for Khiron, and will continue to enable us to improve quality of life for more patients,” Torres added.

Khiron Engages Arrowhead Business and Investment Decisions, LLC to Provide Investor Relations Services

The Company is also pleased to announce that it has retained the services of Arrowhead Business and Investment Decisions, LLC (“Arrowhead”) to provide investor relations services and to develop its knowledge of the international market. Arrowhead will work closely with Khiron to develop and deploy a comprehensive international investor marketing program, which will include the publication of independent analysis, investor targeting, distribution of corporate disclosures, no-deal roadshows, reports and strategic advice. Arrowhead is a leading US-based investor relations firm headquartered in New York City and was established in 2008. Arrowhead advises public companies on investor relations, financial communications and capital markets strategies. As a cross-border specialist, Arrowhead provides idea generation, business insight and access to an international network of institutional and private investors. Through targeting, research and interactions, Arrowhead helps companies and investors assess opportunities, connect, exchange information and complete transactions.

Arrowhead will provide services for an initial term of six months. Cash compensation for services will be US$50,000. Arrowhead is not related to the Company and has no interest, direct or indirect, in the Company or its securities. Arrowhead’s commitment remains subject to TSX Venture Exchange approval.

About Khiron Life Sciences Corp.
Khiron is a leading international vertically integrated medical cannabis company with core businesses in Latin America and Europe. Leveraging 100% owned medical health clinics and proprietary telemedicine platforms, Khiron combines a patient-centric approach, physician training programs, scientific expertise, product innovations and agricultural infrastructure to drive prescriptions and brand loyalty among patients worldwide. The Company has a commercial presence in Colombia, Peru, GermanyUK and Brazil and is well positioned to begin sales in Mexico. The company is led by co-founder and managing director, Alvaro Torresand an experienced and diverse management team and board of directors.

Visit Khiron online at Investors.khiron.ca
Linkedin https://www.linkedin.com/company/khiron-life-sciences-corp/

Cautionary Notes

Forward-looking statements

This press release may contain certain “forward-looking information” and “forward-looking statements” within the meaning of applicable securities laws. All information contained herein that is not historical in nature may constitute forward-looking information. Khiron undertakes no obligation to comment on any analyses, expectations or statements made by third parties regarding Khiron, its securities or its financial or operating results (as applicable). Although Khiron believes that the expectations reflected in the forward-looking statements in this press release are reasonable, these forward-looking statements are based on expectations, factors and assumptions regarding future events which may prove to be inaccurate and are subject to numerous risks and uncertainties. , some of which are beyond Khiron’s control, including the risk factors discussed in Khiron’s Annual Information Form which is available on Khiron’s SEDAR profile at www.sedar.com. The forward-looking information contained in this press release is expressly qualified by this cautionary statement and is made as of the date hereof. Khiron disclaims any intention and has no obligation or liability, except as required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.

Investor contacts:
Paula Ricardo
E: [email protected]
Phone. : +1 (647) 556-5750

Media Contact:
Pierre Leis
Communicating Europe
E: [email protected]

Caroline Gomez
Latin communications
E: [email protected]

Khiron Europe:
Franziska Katterbach, President
E: [email protected]

SOURCEKiron Life Sciences Corp.